<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pelizaeus-Merzbacher disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pelizaeus-Merzbacher disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pelizaeus-Merzbacher disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Amy T Waldman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Francisco González-Scarano, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc C Patterson, MD, FRACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen V Firth, DM, FRCP, FMedSci
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 26, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 1885, Friedrich Pelizaeus first identified a genetic disorder causing spasticity and developmental delay [
         <a href="#rid1">
          1,2
         </a>
         ]. Twenty-five years later, Ludwig Merzbacher further described the neuropathology of 12 affected individuals related to the proband [
         <a href="#rid3">
          3-6
         </a>
         ]. Together, Pelizaeus and Merzbacher identified the X-linked inheritance, the neonatal features, and the hypomyelination of the central nervous system that characterize the disease.
        </p>
        <p>
         Pelizaeus-Merzbacher disease (PMD; MIM 312080) is classified as a dysmyelinating or hypomyelinating disorder, in which normal myelination never occurs, as opposed to a demyelinating disorder, in which normal myelin is later destroyed [
         <a href="#rid7">
          7,8
         </a>
         ]. PMD is caused by pathogenic variants of the gene for proteolipid protein 1 (
         <em>
          PLP1
         </em>
         ; MIM 300401).
        </p>
        <p>
         This topic will review the pathogenesis, clinical features, and diagnosis of PMD and related disorders.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenic variants of the proteolipid protein 1 (
         <em>
          PLP1
         </em>
         ) gene result in a range of phenotypes that form a clinical spectrum  (
         <a class="graphic graphic_figure graphicRef143859" href="/z/d/graphic/143859.html" rel="external">
          figure 1
         </a>
         ), from the more severe PMD at one end to the relatively mild X-linked spastic paraplegia type 2 (SPG2) at the other [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Connatal PMD
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Classic PMD
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          PLP1
         </em>
         null syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypomyelination of early myelinating structures (HEMS)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complicated X-linked spastic paraplegia type 2 (SPG2)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pure SPG2
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Role of
          <i>
           PLP1
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          PLP1
         </em>
         gene encodes both proteolipid protein 1 (PLP1) and myelin DM20 proteolipid protein (DM20), major structural myelin proteins that contribute to the integrity of myelinated axons [
         <a href="#rid10">
          10
         </a>
         ]. PLP1 is the predominant protein constituent of myelin in the central nervous system. Protein DM20 is a spliced isoform of
         <em>
          PLP1
         </em>
         , although it is not as abundant as PLP1 in the mature central nervous system [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Mature oligodendrocytes develop and initiate protein synthesis [
         <a href="#rid11">
          11
         </a>
         ]. DM20 may be responsible for oligodendrocyte differentiation and survival [
         <a href="#rid12">
          12
         </a>
         ], whereas PLP1 is involved in membrane signaling [
         <a href="#rid13">
          13-15
         </a>
         ]. In addition, PLP1 is required for the production and stabilization of compact myelin, likely due to its role in forming integrin receptor adhesion complexes [
         <a href="#rid4">
          4,15
         </a>
         ]. Interruption of the intracellular trafficking and secretory pathways in PMD results in cell death.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Duplications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common pathogenic variant is the duplication of the
         <em>
          PLP1
         </em>
         gene, which accounts for approximately 60 to 70 percent of PMD [
         <a href="#rid12">
          12,16,17
         </a>
         ]. Duplication is caused by unequal sister chromatid exchange in male meiosis [
         <a href="#rid16">
          16,18
         </a>
         ].
        </p>
        <p>
         Duplications of the
         <em>
          PLP1
         </em>
         gene most likely cause overexpression of PLP1, which results in protein accumulation in the late endosomes and lysosomes. After synthesis in the rough endoplasmic reticulum of oligodendrocytes, PLP1 interacts with cholesterol and galactocerebroside in the Golgi to form myelin "rafts." The overexpression of PLP1 overwhelms this process, altering the composition of the rafts, and compromising the structure of the myelin sheath. Lipid rafts are unique structures within the plasma membrane composed primarily of cholesterol, sphingolipids, and scaffolding proteins that are important for vesicular trafficking, signaling mechanisms, and molecular transport. Disruption of these functions results in impaired lipid-lipid, lipid-protein, and membrane-cytoskeletal interactions which have been implicated in many neurologic diseases [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         The size of the
         <em>
          PLP1
         </em>
         duplication is variable and does not correlate with outcome. However, overexpression of PLP1, or the amount of excess protein produced, is associated with the severity of the disease [
         <a href="#rid7">
          7,14
         </a>
         ]. Most patients with duplications of the
         <em>
          PLP1
         </em>
         gene have classic PMD [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="local">
          'Clinical features'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Missense variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protein misfolding caused by pathogenic
         <em>
          PLP1
         </em>
         variants is another likely pathogenic mechanism of PMD [
         <a href="#rid17">
          17
         </a>
         ]. In oligodendrocytes,
         <em>
          PLP1
         </em>
         is synthesized in the rough endoplasmic reticulum and modified in the Golgi complex prior to transport to the myelin membrane.
        </p>
        <p>
         Thus, the accumulation of misfolded PLP1 and DM20 in the endoplasmic reticulum leads to the expression of disease in PMD [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         When both PLP1 and DM20 are not folded properly prior to transport, the misfolded proteins accumulate in the endoplasmic reticulum, resulting in upregulation of genes that induce apoptosis and a more severe disease phenotype [
         <a href="#rid20">
          20
         </a>
         ]. However, when only PLP1 is misfolded, PLP1 is retained in the endoplasmic reticulum, but the oligodendrocyte survives, producing a less severe phenotype [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
         In general, the most severe phenotypes are caused by missense variants, especially amino acid substitutions in highly conserved regions of the protein [
         <a href="#rid14">
          14
         </a>
         ]. Missense variants impair PLP1 protein cellular transport out of the endoplasmic reticulum in oligodendrocytes, which ultimately causes cell death as described above. In the connatal phenotype, a missense variant inhibits both PLP1 and DM20 transport, whereas only PLP1 transport is affected in missense variants that cause classic PMD [
         <a href="#rid7">
          7,21
         </a>
         ]. (See
         <a class="local">
          'Clinical features'
         </a>
         below.)
        </p>
        <p>
         Thus, the accumulation of misfolded PLP1 and DM20 in the endoplasmic reticulum leads to the expression of disease in PMD [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Other variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Conservative amino acid substitutions in less-critical regions of the protein cause a similar, less severe phenotype. Nonsense variants, splice-site variants, and small deletions have also been described [
         <a href="#rid7">
          7,14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Null variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Deletion of the
         <em>
          PLP1
         </em>
         gene or disrupted translation due to a point pathogenic variant at the beginning of the coding region results in a loss of function in which no protein is produced. These null variants cause relatively mild disease, such as mild spastic paraparesis and demyelinating peripheral neuropathy [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Patients without PLP1 and DM20 are still able to form myelin; however, compact sheaths and axonal interactions are defective due to a loss of the structural proteins. The resulting phenotype is less severe than those associated with other pathogenic variants [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="local">
          'Clinical features'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, the estimated prevalence of PMD is between 1:200,000 and 1:500,000 [
         <a href="#rid9">
          9
         </a>
         ]. A retrospective review of 122 children with an inherited leukodystrophy from a regional center in Utah reported that PMD was the etiology in 7.4 percent [
         <a href="#rid23">
          23
         </a>
         ]. In a 2020 report that analyzed data from eight laboratories in the United States over a five-year period, the relative frequency of
         <em>
          PLP1
         </em>
         pathogenic variants determined by whole exome sequencing, gene panel testing, and/or single-gene testing was approximately 8 percent [
         <a href="#rid24">
          24
         </a>
         ]. Of note, PMD may be underrepresented in data from whole exome sequencing due to the variation in laboratory thresholds used to detect deletions and duplications. In Japan, the incidence of PMD due to a
         <em>
          PLP1
         </em>
         pathogenic variant was estimated to be 1.45 per 100,000 male live births [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major features of PMD are nystagmus, spasticity, athetosis, tremor, and ataxia. The symptoms vary in onset and severity, thereby producing a clinical spectrum of disease.
        </p>
        <p>
         Various forms or phenotypes of PMD are distinguished by the severity of disease and other clinical features. These are connatal, classic, and transitional PMD; X-linked spastic paraplegia type 2 (SPG2); and proteolipid protein 1 (
         <em>
          PLP1
         </em>
         ) null syndrome. These phenotypes of PMD do not necessarily represent distinct clinical syndromes, as overlap exists [
         <a href="#rid4">
          4,26,27
         </a>
         ].
        </p>
        <p>
         While PMD is an X-linked disease, female carriers may develop mild to moderate neurologic manifestations. (See
         <a class="local">
          'Carrier females'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Connatal PMD
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most severe form, connatal PMD, presents at birth or during the first weeks of life with pendular nystagmus, hypotonia, respiratory distress, pharyngeal weakness, and stridor. Affected males later develop significant spasticity and have little voluntary muscle control. They have significant head lag and cannot sit unsupported or ambulate. The motor difficulties extend to their expressive language, which usually does not develop, but they may develop receptive language. Cognitive impairment is likely. Pharyngeal weakness causes swallowing difficulties, and infants can have stridor, optic atrophy, and seizures [
         <a href="#rid6">
          6,9
         </a>
         ].
        </p>
        <p>
         Most children with connatal PMD die before the age of 10 because of aspiration, but survival until the second or third decade has been reported [
         <a href="#rid6">
          6,9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Classic PMD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classic PMD, the most common form of the disease, also presents early, within the first five years of life [
         <a href="#rid9">
          9
         </a>
         ]. Nystagmus is often detected in infancy within the first two to four months of life. Affected males later develop hypotonia with lower extremity weakness, trunk and limb ataxia, and head titubation. The motor milestones are delayed, and children develop spastic quadriparesis. Most children never walk independently. Language function can be normal, although dysarthria and cognitive impairments are common. The affected patients do not have any respiratory involvement and can survive until the third to seventh decade of life [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Transitional form
         </span>
         <span class="headingEndMark">
          —
         </span>
         A transitional form between the connatal and classic forms has been proposed for patients with overlapping features involving the onset and severity of symptoms [
         <a href="#rid9">
          9,18
         </a>
         ]. However, with variation in phenotypes and the age proximity between the connatal and classic forms, the utility of this subtype has been questioned [
         <a href="#rid4">
          4,21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          X-linked spastic paraplegia type 2
         </span>
         <span class="headingEndMark">
          —
         </span>
         A milder form of PMD is known as X-linked SPG2  (
         <a class="graphic graphic_figure graphicRef143859" href="/z/d/graphic/143859.html" rel="external">
          figure 1
         </a>
         ). Despite a delay in gross motor skills, many children learn to walk independently, although they may become nonambulatory as they develop mild to severe spasticity. They also have a spastic urinary bladder.
        </p>
        <p>
         Patients with SPG2 can be further subdivided into complicated spastic paraplegia and uncomplicated spastic paraplegia [
         <a href="#rid5">
          5,9
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complicated spastic paraplegia presents in the first five years of life and is similar to the other types of PMD in which patients have limb and truncal ataxia and nystagmus. There may be mild cognitive impairment. Affected individuals survive until the fourth to seventh decade.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uncomplicated spastic paraplegia typically presents in the first five years of life although some have presented as late as the fourth decade. Uncomplicated spastic paraplegia has no other signs of central nervous system involvement, aside from the spastic paraparesis and urinary bladder. Cognition and lifespan are normal.
        </p>
        <p>
        </p>
        <p>
         Males with SPG2 can reproduce, in contrast to all other forms of PMD [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          <i>
           PLP1
          </i>
          null syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         A subset of patients with null variants presents in the first five years of life with mild spastic quadriparesis, mostly affecting the lower extremities [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="local">
          'Null variants'
         </a>
         above.)
        </p>
        <p>
         Patients with the null syndrome are generally able to ambulate despite the increased tone. They have ataxia but not nystagmus. While they have mild to moderate cognitive difficulties, language skills develop initially. The
         <em>
          PLP1
         </em>
         null syndrome is further distinguished from other forms of PMD by the presence of a mild multifocal demyelinating peripheral neuropathy [
         <a href="#rid9">
          9,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Carrier females
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although PMD is an X-linked disorder, women who are heterozygous carriers may be symptomatic. Some adult females may exhibit a spastic gait or a mild peripheral neuropathy, urinary dysfunction, or (rarely) cognitive impairment or psychosis [
         <a href="#rid29">
          29
         </a>
         ]. There is a paradoxical relationship between the disease severity in men and affected women, which is that women from families with mildly affected males are more likely to have neurologic symptoms than women with severely affected relatives.
        </p>
        <p>
         This paradox is explained by the random inactivation of the X chromosome that results in an average 50 percent expression of the abnormal protein [
         <a href="#rid20">
          20
         </a>
         ]. In heterozygous females, the oligodendrocytes that express the severe pathogenic variant undergo apoptosis. In time, the normal oligodendrocytes (those that express the other X chromosome) produce a sufficient amount of PLP1 protein to compensate for the loss. However, in heterozygous women who have the less severe pathogenic variants, apoptosis of the abnormal oligodendrocytes does not take place, and those women end up with abnormal myelin, resulting in neurologic dysfunction [
         <a href="#rid6">
          6,9,30
         </a>
         ]. There is a single case report of a woman presenting in infancy with a "classic" male phenotype characterized by nystagmus, spasticity, and significant motor delay [
         <a href="#rid31">
          31
         </a>
         ]. Genetic testing revealed a deletion of exons 1 to 7 of the
         <em>
          PLP1
         </em>
         gene and nonrandom skewed X chromosome inactivation, suggesting preferential activation of the X chromosome with the deletion.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         An appreciation of the normal appearance of unmyelinated and myelinated white matter structures on brain magnetic resonance imaging (MRI) is helpful for understanding imaging studies of infants and children with a hypomyelinating leukodystrophy [
         <a href="#rid32">
          32-34
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unmyelinated white matter has a high signal intensity on T2-weighted and low signal on T1-weighted images
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myelinated white matter has a low signal intensity on T2-weighted and a high signal intensity on T1-weighted images
        </p>
        <p>
        </p>
        <p>
         In normal development, the bulk of central nervous system myelination occurs during the first two years of life [
         <a href="#rid32">
          32
         </a>
         ]. Thus, in infants younger than two years with a dysmyelination syndrome, the brain MRI may not show obvious white matter abnormalities.
        </p>
        <p>
         In normal full-term infants, myelination is usually evident on MRI in the pons and cerebellum, and by the age of three months, normal infants show myelination in the posterior limb of the internal capsule, splenium of the corpus callosum, and optic radiations [
         <a href="#rid32">
          32
         </a>
         ]. Absence of these MRI findings suggests the diagnosis of a dysmyelinating syndrome such as PMD [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         The brain MRI of older children with the PMD phenotype often reveals diffuse leukodystrophy with increased signal intensity in the cerebral hemispheres, cerebellum, and brainstem on T2-weighted or fluid-attenuated inversion recovery (FLAIR) sequences  (
         <a class="graphic graphic_diagnosticimage graphicRef51393" href="/z/d/graphic/51393.html" rel="external">
          image 1
         </a>
         ). However, many hypomyelinating disorders have diffuse involvement, unlike the demyelinating disorders where regional involvement is easily identified on T2-weighted and FLAIR sequences. The T1-weighted images are also critical in identifying hypomyelinating disorders, such as PMD, as the white matter will also appear diffusely abnormal with mild T1 hypointensity, isointensity, or hyperintensity [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         No clear correlation between genotype, clinical phenotype, and MRI phenotype has been established for PMD [
         <a href="#rid35">
          35
         </a>
         ]. However, some experts have noted an inverse correlation between the amount of myelin present and the clinical disease severity [
         <a href="#rid33">
          33,36
         </a>
         ]. As an example, no myelin is present at all in some infants with connatal PMD, the most severe form of PMD [
         <a href="#rid33">
          33
         </a>
         ]. Diffuse brainstem or corticospinal tract involvement of the posterior limb of the internal capsule (hyperintensity on T2-weighted imaging) predicted patients with poorer motor outcomes in a cohort of 19 subjects [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         In patients with the classic PMD phenotype, the white matter abnormalities on MRI have been divided into three subtypes [
         <a href="#rid37">
          37
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type I: diffuse abnormality in the hemispheres with lesions affecting the corticospinal tracts; this type was found in patients with a
         <em>
          PLP1
         </em>
         duplication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type II: similar hemispheric lesions without corticospinal involvement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type III: patchy hemispheric involvement. The patchy areas of myelin forming the "tigroid" pattern are not readily apparent on neuroimaging in most patients [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The reported abnormalities on T2 MRI in SPG2 range from discrete or patchy hyperintensities to more diffuse leukoencephalopathy [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p>
         Studies evaluating magnetic resonance spectroscopy (MRS) in patients with PMD have found no consistent pattern of abnormalities. Some patients, particularly those with the
         <em>
          PLP1
         </em>
         null syndrome, may show reduced white matter N-acetylaspartate (NAA) levels [
         <a href="#rid40">
          40,41
         </a>
         ], while others, mainly those with
         <em>
          PLP1
         </em>
         duplications, may have increased white matter NAA levels [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Pathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Merzbacher originally described the absence of myelin sheaths specific to the central nervous system without axonal involvement and preserved myelin islets around blood vessels [
         <a href="#rid2">
          2
         </a>
         ]. These patchy areas of myelin islands give the tissue a "tigroid" appearance [
         <a href="#rid7">
          7,43
         </a>
         ].
        </p>
        <p>
         Gross sections of the brain reveal atrophy, pallor, and sclerosis of white matter in the cerebrum, cerebellum, and brainstem [
         <a href="#rid8">
          8
         </a>
         ]. The axons of the central nervous system lack the typical myelin sheath. In addition, there is a profound loss of oligodendrocytes, which produce myelin. Although not as remarkable, axonal damage has been demonstrated, likely due to impaired axonal transport from altered proteolipid protein-mediated oligodendrocyte-axonal interactions [
         <a href="#rid6">
          6,43
         </a>
         ]. The axons do not appear to be affected by demyelination or oligodendrocyte cell death.
        </p>
        <p>
         The peripheral nervous system is unaffected in most forms of PMD; an exception is the
         <em>
          PLP1
         </em>
         null syndrome. (See
         <a class="local">
          'PLP1 null syndrome'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of PMD or X-linked spastic paraplegia type 2 (SPG2) is suspected in patients with the characteristic clinical and brain MRI features, particularly if there is a family history consistent with X-linked disease inheritance, although de novo single-nucleotide variants do occur [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
         The diagnosis should be confirmed, when possible, by genetic testing. Nerve conduction studies to assess peripheral nerve function may be helpful for identifying individuals with the proteolipid protein 1 (
         <em>
          PLP1
         </em>
         ) null syndrome [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="local">
          'PLP1 null syndrome'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of PMD is confirmed by demonstrating a heterozygous pathogenic variant in the
         <em>
          PLP1
         </em>
         gene. Approximately 80 percent of males with clinically diagnosed PMD or SPG2 have
         <em>
          PLP1
         </em>
         pathogenic variants [
         <a href="#rid9">
          9
         </a>
         ]. The genetic etiology for patients with clinical features of PMD but without pathogenic
         <em>
          PLP1
         </em>
         variants remains unknown, with the exception of Pelizaeus-Merzbacher-like disease. (See
         <a class="local">
          'Pelizaeus-Merzbacher-like disease'
         </a>
         below.)
        </p>
        <p>
         Duplication of the
         <em>
          PLP1
         </em>
         gene is the most common defect, accounting for approximately 60 percent or more of identified pathogenic variants; deletions of the
         <em>
          PLP1
         </em>
         gene account for ≤2 percent of PMD cases [
         <a href="#rid9">
          9
         </a>
         ]. Therefore, the recommended initial genetic screening test in a patient with classic symptoms and MRI findings is a search for duplications or deletions [
         <a href="#rid9">
          9,12
         </a>
         ]. Complex duplication-inverted triplication-duplication (DUP-TRP/INV-DUP) rearrangements of the
         <em>
          PLP1
         </em>
         gene have also been reported [
         <a href="#rid44">
          44,45
         </a>
         ]. If these explorations of
         <em>
          PLP1
         </em>
         are nondiagnostic, next-generation methods (eg, using a gene panel or whole exome sequencing) should be pursued. Of note, for patients who do not have the classic clinical features or MRI findings for PMD, many experts advocate for the gene panel or whole exome sequencing approach as initial testing to increase diagnostic yield and reduce the time to diagnosis for families [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Genetic analysis of the
         <em>
          GJC2
         </em>
         (formerly
         <em>
          GJA12
         </em>
         ) gene should be considered if inheritance is autosomal recessive, the proband is female, or all the mutational mechanisms in
         <em>
          PLP1
         </em>
         gene have been excluded. (See
         <a class="local">
          'Pelizaeus-Merzbacher-like disease'
         </a>
         below.)
        </p>
        <p>
         Prenatal testing, using amniocentesis and chorionic villus sampling, has been used to detect pathogenic variants of
         <em>
          PLP1
         </em>
         in at-risk fetuses [
         <a href="#rid47">
          47-49
         </a>
         ]. Preimplantation genetic testing following in vitro fertilization may be an option for some couples.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis for PMD and X-linked spastic paraplegia type 2 (SPG2) includes Pelizaeus-Merzbacher-like disease (PMLD), other leukodystrophies  (
         <a class="graphic graphic_algorithm graphicRef65871" href="/z/d/graphic/65871.html" rel="external">
          algorithm 1
         </a>
         ), and inherited disorders with spastic paraplegia.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Pelizaeus-Merzbacher-like disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         PMLD shares similar clinical features with PMD, such as early-onset nystagmus, delayed motor milestones, spasticity, ataxia, partial seizures, and a mild peripheral neuropathy [
         <a href="#rid50">
          50
         </a>
         ]. However, PMLD is not associated with pathogenic variants or duplications of the proteolipid protein 1 (
         <em>
          PLP1
         </em>
         ) gene. The disorder appears to be genetically heterogeneous.
        </p>
        <p>
         Some cases of PMLD are associated with dysmyelination, demyelination, autosomal recessive inheritance, and pathogenic variants of the gap junction protein gamma-2 gene (
         <em>
          GJC2
         </em>
         ), formerly known as the
         <em>
          GJA12
         </em>
         gene on chromosome 1q41-q42 [
         <a href="#rid50">
          50-54
         </a>
         ]. The
         <em>
          GJC2
         </em>
         gene encodes a gap junction protein that is highly expressed in oligodendrocytes [
         <a href="#rid50">
          50
         </a>
         ]. Pathogenic variants have been identified in the promoter and non-coding exon in addition to the coding region of the gene [
         <a href="#rid54">
          54-56
         </a>
         ]. Therefore, sequencing of the only the latter may result in delayed or missed diagnosis.
        </p>
        <p>
         Another study screened
         <em>
          PLP1
         </em>
         -negative patients from a cohort of 53 families with X-linked hypomyelinated leukoencephalopathies of unknown etiology [
         <a href="#rid57">
          57
         </a>
         ]. Pathogenic variants in the
         <em>
          SLC16A2
         </em>
         gene (causing Allan-Herndon-Dudley syndrome) were present in 11 percent. Boys with
         <em>
          SLC16A2
         </em>
         pathogenic variants presented before six months of age with severe forms of PMLD and marked hypomyelination on brain MRI. The hypomyelination improved during follow-up, suggesting that pathogenic
         <em>
          SLC16A2
         </em>
         variants cause a severe delay of myelination rather than a permanent myelin defect. However, there was no neurologic improvement.
        </p>
        <p>
         The
         <em>
          SLC16A2
         </em>
         gene encodes a thyroid hormone transporter, which appears to play an important role in the movement of thyroid hormone into the brain and therefore in the effect of thyroid hormone on brain development [
         <a href="#rid58">
          58
         </a>
         ]. Three patients with PMLD and pathogenic
         <em>
          SLC16A2
         </em>
         variants who had thyroid function testing showed increased free T3, low free T4, and normal thyroid stimulating hormone levels [
         <a href="#rid57">
          57
         </a>
         ], a profile associated with a thyroid hormone cell transporter defect. (See
         <a class="medical medical_review" href="/z/d/html/132665.html" rel="external">
          "Genetic defects in thyroid hormone transport and metabolism", section on 'Thyroid hormone cell membrane transport defect'
         </a>
         .)
        </p>
        <p>
         Pathogenic variants in
         <em>
          RARS
         </em>
         have been reported in four individuals who developed nystagmus at variable ages (five months to three years), along with spastic diplegia, developmental regression, and cerebellar signs [
         <a href="#rid59">
          59
         </a>
         ]. MRI of the brain revealed hypomyelination of the supratentorial (and, in one patient, infratentorial) white matter. Brain atrophy also occurs.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Hypomyelinating leukodystrophies
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of rare metabolic disorders are characterized by hypomyelination (ie, a failure to develop normal myelin). However, with the exception of PMLD, discussed above, most of these disorders are unlikely to be confused with PMD either because they lack the characteristic clinical features (ie, nystagmus, spasticity, athetosis, tremor, and ataxia), or because they have distinctive clinical features not associated with PMD (eg, the unique MRI pattern of hypomyelination with atrophy of the basal ganglia and cerebellum) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The 18q deletion syndrome (MIM 601808) is characterized by intellectual disability, hearing impairment, short stature, hypotonia, and foot deformities. Diffuse symmetric deep white matter hypomyelination is seen on brain MRI. In some cases, focal subcortical white matter abnormalities or abnormal T2 signal hypointensity in the basal ganglia and/or thalami are noted [
         <a href="#rid60">
          60-63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cockayne syndrome (MIM 216400 and MIM 133540) is characterized by severe physical and intellectual disability, short stature, microcephaly, retinal degeneration, kyphoscoliosis, gait defects, sun sensitivity, and white matter hypomyelination with atrophy of the cerebrum and cerebellum. (See
         <a class="medical medical_review" href="/z/d/html/6226.html" rel="external">
          "Neuropathies associated with hereditary disorders", section on 'Cockayne syndrome'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC) is characterized by normal or delayed early development followed by progressive extrapyramidal symptoms, ataxia, and spasticity. Cognition is variably affected. Brain MRI demonstrates atrophy of the cerebral white matter, basal ganglia, and cerebellum [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypomyelination with congenital cataracts (MIM 610532) is characterized by bilateral congenital cataracts, developmental delay, and slowly progressive neurological impairment, with spasticity, ataxia, and intellectual disability. Hypomyelination involves both the central and peripheral nervous systems [
         <a href="#rid66">
          66,67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A number of hypomyelinating leukodystrophies are caused by autosomal recessive pathogenic variants in the
         <em>
          POLR3A
         </em>
         or
         <em>
          POLR3B
         </em>
         genes, which encode for the two largest subunits of RNA polymerase III (Pol III) [
         <a href="#rid68">
          68
         </a>
         ]. These Pol III-related leukodystrophies share clinical and neuroimaging features, and include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypomyelination with hypogonadotropic hypogonadism and hypodontia (4H syndrome) [
         <a href="#rid69">
          69-72
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Leukodystrophy with oligodontia [
         <a href="#rid73">
          73
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ataxia, delayed dentition, and hypomyelination [
         <a href="#rid74">
          74
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tremor-ataxia with central hypomyelination [
         <a href="#rid75">
          75
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum [
         <a href="#rid76">
          76
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Major clinical findings are motor dysfunction (spasticity, cerebellar ataxia, and/or tremor), abnormal dentition, and hypogonadotropic hypogonadism [
         <a href="#rid77">
          77
         </a>
         ]. The predominant abnormalities detected by MRI include diffuse hypomyelination, hypointense T2-weighted signal of the bilateral globi pallidi, anterolateral thalamic nuclei, dentate nuclei, and pyramidal tracts, and cerebellar atrophy [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sialic acid storage disease (also called Salla disease or sialuria) is an autosomal recessive disorder with a variable phenotype, ranging from a severe infantile form (MIM 269920) to a milder adult form (MIM 604369) that is prevalent in Finland. Typical clinical features include hypotonia, cerebellar ataxia, and intellectual disability. In infants, visceromegaly and coarse features are additional features. Brain MRI demonstrates progressive cerebellar atrophy and dysmyelination [
         <a href="#rid79">
          79-83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trichothiodystrophy with photosensitivity (also known as Tay syndrome; MIM 601675) is characterized by sulfur-deficient brittle hair and nails, ichthyosis, short stature, intellectual disability, and pyramidal tract signs. Photosensitivity affects approximately half of the patients. Brain MRI reveals severe cerebral hypomyelination and patchy cerebellar hypomyelination [
         <a href="#rid84">
          84,85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Other leukodystrophies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Leukodystrophies that may present in infancy and childhood include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alexander disease (see
         <a class="medical medical_review" href="/z/d/html/1695.html" rel="external">
          "Alexander disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Childhood ataxia with central nervous system hypomyelination/vanishing white matter disease (see
         <a class="medical medical_review" href="/z/d/html/1701.html" rel="external">
          "Vanishing white matter disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Krabbe disease (see
         <a class="medical medical_review" href="/z/d/html/6188.html" rel="external">
          "Krabbe disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metachromatic leukodystrophy (see
         <a class="medical medical_review" href="/z/d/html/6195.html" rel="external">
          "Metachromatic leukodystrophy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         X-linked adrenoleukodystrophy (see
         <a class="medical medical_review" href="/z/d/html/6200.html" rel="external">
          "Clinical features, evaluation, and diagnosis of X-linked adrenoleukodystrophy"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Unlike PMD, these leukodystrophies do not typically present with nystagmus [
         <a href="#rid9">
          9
         </a>
         ]. Furthermore, brain MRI abnormalities are typically diffuse in PMD, but usually have a regional predilection in the other leukodystrophies.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Canavan disease is a neurodegenerative disease characterized by leukodystrophy and spongy degeneration of the brain that typically presents in early infancy with macrocephaly, hypotonia, and optic atrophy. Later, hypertonia, seizures, and progressive neurologic deterioration occur. Nystagmus is not a typical feature. On neuroimaging, there is diffuse cerebral white matter degeneration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Classic (merosin deficient) congenital muscular dystrophy is associated with demyelination of the cerebral hemispheres without structural central nervous system anomalies. Clinical features include hypotonia and weakness, but unlike PMD, there is no nystagmus. MRI shows extensive cerebral white matter changes [
         <a href="#rid86">
          86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6180.html" rel="external">
          "Oculopharyngeal, distal, and congenital muscular dystrophies", section on 'Congenital muscular dystrophies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Hereditary spastic paraplegia
         </span>
         <span class="headingEndMark">
          —
         </span>
         As discussed above, SPG2 is a milder form of PMD that can present in the first five years of life, and less often in adulthood  (
         <a class="graphic graphic_figure graphicRef143859" href="/z/d/graphic/143859.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'X-linked spastic paraplegia type 2'
         </a>
         above.)
        </p>
        <p>
         In fact, SPG2 is one of the many genetic causes  (
         <a class="graphic graphic_table graphicRef95449" href="/z/d/graphic/95449.html" rel="external">
          table 1
         </a>
         ) of hereditary spastic paraplegia (HSP), an inherited syndrome that is characterized clinically by progressive leg weakness and spasticity. HSP is classified by mode of inheritance, chromosomal locus, or causative gene; genetic loci for HSP are designated "spastic gait" (SPG) loci 1 through 20 in order of their discovery. With the exception of SPG2, neuroimaging of the brain and spinal cord by MRI is normal in most types of HSP. (See
         <a class="medical medical_review" href="/z/d/html/14152.html" rel="external">
          "Hereditary spastic paraplegia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         No disease modifying treatment is available for PMD, X-linked spastic paraplegia type 2 (SPG2), or Pelizaeus-Merzbacher-like disease (PMLD).
        </p>
        <p>
         Management is multidisciplinary and supportive [
         <a href="#rid9">
          9,87
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optimal care may require specialists in neurology, physical medicine, orthopedics, pulmonary medicine, and gastroenterology, and physical, occupational, and speech therapy. Wheelchairs are often required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Scoliosis may cause pulmonary compromise and pain. Prevention measures include proper seating in the wheelchair and ongoing physical therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aspiration is a major cause of morbidity and mortality. Patients with swallowing difficulties may require a gastrostomy tube.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assistive devices for joint contractures are frequently needed. Antispasticity medications, such as oral
         <a class="drug drug_pediatric" data-topicid="13223" href="/z/d/drug information/13223.html" rel="external">
          diazepam
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="112669" href="/z/d/drug information/112669.html" rel="external">
          tizanidine
         </a>
         , and intrathecal or oral
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          baclofen
         </a>
         , may improve tone. Surgical release of joint contractures may be required in severe cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizures are usually restricted to the more severe syndromes, such as connatal PMD, and typically respond to antiepileptic medications. (See
         <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">
          "Seizures and epilepsy in children: Initial treatment and monitoring"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">
          "Overview of the management of epilepsy in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Developmental assessment is important for infants and children with proteolipid protein 1 (
         <em>
          PLP1
         </em>
         )-related disorders. Specialized education is typically necessary. Communication devices may be useful in children with impaired vision and hearing.
        </p>
        <p>
        </p>
        <p>
         Umbilical cord blood transplantation has been performed in selected patients with leukodystrophies, but in the absence of a control group or natural history data, it is unclear if this procedure improves neurologic outcomes. In one report, two boys with PMD (ages 9 and 29 months, respectively, at the time of transplant) demonstrated successful engraftment after the procedure [
         <a href="#rid88">
          88
         </a>
         ]. The post-transplantation course was complicated by graft-versus-host disease for both, and one boy developed autoimmune hemolytic anemia and thrombocytopenia requiring long-term use of glucocorticoids with subsequent adrenal insufficiency and immunosuppression. While the authors report improvements in cognition and interval myelination on MRI, the boys continued to have cognitive impairments and both had significant motor delays.
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pelizaeus-Merzbacher disease (PMD) is a dysmyelinating disorder, in which normal myelination never occurs.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pathogenic variants of the proteolipid protein 1 (
         <em>
          PLP1
         </em>
         ) gene result in a range of phenotypes that form a clinical spectrum  (
         <a class="graphic graphic_figure graphicRef143859" href="/z/d/graphic/143859.html" rel="external">
          figure 1
         </a>
         ), from the more severe PMD at one end, to the relatively mild X-linked spastic paraplegia type 2 (SPG2) at the other. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most cases of PMD are caused by duplication of the
         <em>
          PLP1
         </em>
         gene, which most likely causes overexpression of PLP1, resulting in compromise of the myelin sheath structure. Protein misfolding caused by
         <em>
          PLP1
         </em>
         missense variants is a second likely pathogenic mechanism of PMD. A third mechanism involves null variants leading to a loss of function in which no protein is produced. These cause relatively mild disease. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The major clinical features of PMD are nystagmus, spasticity, athetosis, tremor, and ataxia. The symptoms vary in onset and severity, thereby producing a clinical spectrum of disease. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Various forms or phenotypes of PMD are distinguished by severity of disease and other clinical features. These are:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Connatal
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Classic
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Transitional
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         X-linked SPG2
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          PLP1
         </em>
         null syndrome
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although PMD is an X-linked disease, female carriers may develop mild to moderate neurologic manifestations. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Brain MRI of patients with the PMD phenotype reveals patchy or diffuse leukodystrophy with increased signal intensity in the cerebral hemispheres, cerebellum, and brainstem on T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences. (See
         <a class="local">
          'Neuroimaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gross sections of the brain reveal atrophy, pallor, and sclerosis of white matter in the cerebrum, cerebellum, and brainstem. The axons of the central nervous system lack the typical myelin sheath. (See
         <a class="local">
          'Pathology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinical diagnosis of PMD or SPG2 should be suspected in patients with the characteristic nystagmus and brain MRI findings, particularly if they have a family history consistent with X-linked disease inheritance. The diagnosis is confirmed by demonstrating a pathogenic variant in the
         <em>
          PLP1
         </em>
         gene. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The differential diagnosis for PMD and SPG2 includes Pelizaeus-Merzbacher-like disease (PMLD), other leukodystrophies, and hereditary spastic paraplegia. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is no effective treatment for PMD, SPG2, or PMLD. Management is multidisciplinary and supportive. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Pelizaeus F. Uber eine eigenthümliche form spastischer Lähmung mit cerebralerscheinungen auf hereditärer Grundlage (Multiple Sklerose). Arch Psychiatr Nervenkr 1885; 16:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osaka H, Kawanishi C, Inoue K, et al. Pelizaeus-Merzbacher disease: three novel mutations and implication for locus heterogeneity. Ann Neurol 1999; 45:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merzbacher L. Eine eigenartige familiar-hereditäre Erkrankungsform (Aplasia axialis extra-corticalis congenital). Z Ges Neurol Psych 1910; 3:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodes ME, Pratt VM, Dlouhy SR. Genetics of Pelizaeus-Merzbacher disease. Dev Neurosci 1993; 15:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hudson LD. Pelizaeus-Merzbacher disease and spastic paraplegia type 2: two faces of myelin loss from mutations in the same gene. J Child Neurol 2003; 18:616.
          </a>
         </li>
         <li class="breakAll">
          Garbern JY. Leukodystrophies. In: Neurogenetics: Clinical and Scientific Advances, Lynch DR (Ed), Taylor and Francis, New York 2005. p.469.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takanashi J, Sugita K, Tanabe Y, et al. MR-revealed myelination in the cerebral corticospinal tract as a marker for Pelizaeus-Merzbacher's disease with proteolipid protein gene duplication. AJNR Am J Neuroradiol 1999; 20:1822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gencic S, Abuelo D, Ambler M, Hudson LD. Pelizaeus-Merzbacher disease: an X-linked neurologic disorder of myelin metabolism with a novel mutation in the gene encoding proteolipid protein. Am J Hum Genet 1989; 45:435.
          </a>
         </li>
         <li class="breakAll">
          Wolf NI, van Spaendonk RML, Hobson GM, et al. PLP1 disorders. In: GeneReviews, Adam MP, Ardinger HH, Pagon RA, et al. (Eds), University of Washington, Seattle 2019. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1182/ (Accessed on July 23, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khalaf G, Mattern C, Begou M, et al. Mutation of Proteolipid Protein 1 Gene: From Severe Hypomyelinating Leukodystrophy to Inherited Spastic Paraplegia. Biomedicines 2022; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stecca B, Southwood CM, Gragerov A, et al. The evolution of lipophilin genes from invertebrates to tetrapods: DM-20 cannot replace proteolipid protein in CNS myelin. J Neurosci 2000; 20:4002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang PJ, Hwu WL, Lee WT, et al. Duplication of proteolipid protein gene: a possible major cause of Pelizaeus-Merzbacher disease. Pediatr Neurol 1997; 17:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue K, Osaka H, Kawanishi C, et al. Mutations in the proteolipid protein gene in Japanese families with Pelizaeus-Merzbacher disease. Neurology 1997; 48:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffmann R, Boespflüg-Tanguy O. An update on the leukodsytrophies. Curr Opin Neurol 2001; 14:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gudz TI, Schneider TE, Haas TA, Macklin WB. Myelin proteolipid protein forms a complex with integrins and may participate in integrin receptor signaling in oligodendrocytes. J Neurosci 2002; 22:7398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mimault C, Giraud G, Courtois V, et al. Proteolipoprotein gene analysis in 82 patients with sporadic Pelizaeus-Merzbacher Disease: duplications, the major cause of the disease, originate more frequently in male germ cells, but point mutations do not. The Clinical European Network on Brain Dysmyelinating Disease. Am J Hum Genet 1999; 65:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbern JY. Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis. Cell Mol Life Sci 2007; 64:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue K, Osaka H, Imaizumi K, et al. Proteolipid protein gene duplications causing Pelizaeus-Merzbacher disease: molecular mechanism and phenotypic manifestations. Ann Neurol 1999; 45:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benarroch EE. Lipid rafts, protein scaffolds, and neurologic disease. Neurology 2007; 69:1635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Southwood C, Gow A. Molecular pathways of oligodendrocyte apoptosis revealed by mutations in the proteolipid protein gene. Microsc Res Tech 2001; 52:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gow A, Lazzarini RA. A cellular mechanism governing the severity of Pelizaeus-Merzbacher disease. Nat Genet 1996; 13:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gow A, Southwood CM, Lazzarini RA. Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease. J Cell Biol 1998; 140:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonkowsky JL, Nelson C, Kingston JL, et al. The burden of inherited leukodystrophies in children. Neurology 2010; 75:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt JL, Pizzino A, Nicholl J, et al. Estimating the relative frequency of leukodystrophies and recommendations for carrier screening in the era of next-generation sequencing. Am J Med Genet A 2020; 182:1906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Numata Y, Gotoh L, Iwaki A, et al. Epidemiological, clinical, and genetic landscapes of hypomyelinating leukodystrophies. J Neurol 2014; 261:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulloche J, Aicardi J. Pelizaeus-Merzbacher disease: clinical and nosological study. J Child Neurol 1986; 1:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cailloux F, Gauthier-Barichard F, Mimault C, et al. Genotype-phenotype correlation in inherited brain myelination defects due to proteolipid protein gene mutations. Clinical European Network on Brain Dysmyelinating Disease. Eur J Hum Genet 2000; 8:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbern JY, Yool DA, Moore GJ, et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 2002; 125:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurst S, Garbern J, Trepanier A, Gow A. Quantifying the carrier female phenotype in Pelizaeus-Merzbacher disease. Genet Med 2006; 8:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivakumar K, Sambuughin N, Selenge B, et al. Novel exon 3B proteolipid protein gene mutation causing late-onset spastic paraplegia type 2 with variable penetrance in female family members. Ann Neurol 1999; 45:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brender T, Wallerstein D, Sum J, Wallerstein R. Unusual presentation of pelizaeus-merzbacher disease: female patient with deletion of the proteolipid protein 1 gene. Case Rep Genet 2015; 2015:453105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barkovich AJ. Magnetic resonance techniques in the assessment of myelin and myelination. J Inherit Metab Dis 2005; 28:311.
          </a>
         </li>
         <li class="breakAll">
          van der Knaap MS, Valk J. Pelizaeus-Merzbacher disease and X-linked spastic paraplegia type 2. In: Magnetic Resonance of Myelination and Myelin Disorders, 3rd ed, Springer, New York 1999. p.276.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffmann R, van der Knaap MS. Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 2009; 72:750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mierzewska H, Jamroz E, Mazurczak T, et al. Pelizaeus-Merzbacher disease in patients with molecularly confirmed diagnosis. Folia Neuropathol 2016; 54:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sumida K, Inoue K, Takanashi J, et al. The magnetic resonance imaging spectrum of Pelizaeus-Merzbacher disease: A multicenter study of 19 patients. Brain Dev 2016; 38:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nezu A, Kimura S, Takeshita S, et al. An MRI and MRS study of Pelizaeus-Merzbacher disease. Pediatr Neurol 1998; 18:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cambi F, Tartaglino L, Lublin F, McCarren D. X-linked pure familial spastic paraparesis. Characterization of a large kindred with magnetic resonance imaging studies. Arch Neurol 1995; 52:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodes ME, Zimmerman AW, Aydanian A, et al. Different mutations in the same codon of the proteolipid protein gene, PLP, may help in correlating genotype with phenotype in Pelizaeus-Merzbacher disease/X-linked spastic paraplegia (PMD/SPG2). Am J Med Genet 1999; 82:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonavita S, Schiffmann R, Moore DF, et al. Evidence for neuroaxonal injury in patients with proteolipid protein gene mutations. Neurology 2001; 56:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plecko B, Stöckler-Ipsiroglu S, Gruber S, et al. Degree of hypomyelination and magnetic resonance spectroscopy findings in patients with Pelizaeus Merzbacher phenotype. Neuropediatrics 2003; 34:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takanashi J, Inoue K, Tomita M, et al. Brain N-acetylaspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication. Neurology 2002; 58:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbern J, Cambi F, Shy M, Kamholz J. The molecular pathogenesis of Pelizaeus-Merzbacher disease. Arch Neurol 1999; 56:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck CR, Carvalho CM, Banser L, et al. Complex genomic rearrangements at the PLP1 locus include triplication and quadruplication. PLoS Genet 2015; 11:e1005050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimojima K, Mano T, Kashiwagi M, et al. Pelizaeus-Merzbacher disease caused by a duplication-inverted triplication-duplication in chromosomal segments including the PLP1 region. Eur J Med Genet 2012; 55:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parikh S, Bernard G, Leventer RJ, et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab 2015; 114:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue K, Kanai M, Tanabe Y, et al. Prenatal interphase FISH diagnosis of PLP1 duplication associated with Pelizaeus-Merzbacher disease. Prenat Diagn 2001; 21:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Regis S, Filocamo M, Mazzotti R, et al. Prenatal diagnosis of Pelizaeus-Merzbacher disease: detection of proteolipid protein gene duplication by quantitative fluorescent multiplex PCR. Prenat Diagn 2001; 21:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbern J, Hobson G. Prenatal diagnosis of Pelizaeus-Merzbacher disease. Prenat Diagn 2002; 22:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uhlenberg B, Schuelke M, Rüschendorf F, et al. Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease. Am J Hum Genet 2004; 75:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf NI, Cundall M, Rutland P, et al. Frameshift mutation in GJA12 leading to nystagmus, spastic ataxia and CNS dys-/demyelination. Neurogenetics 2007; 8:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orthmann-Murphy JL, Enriquez AD, Abrams CK, Scherer SS. Loss-of-function GJA12/Connexin47 mutations cause Pelizaeus-Merzbacher-like disease. Mol Cell Neurosci 2007; 34:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henneke M, Combes P, Diekmann S, et al. GJA12 mutations are a rare cause of Pelizaeus-Merzbacher-like disease. Neurology 2008; 70:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer E, Kurian MA, Morgan NV, et al. Promoter mutation is a common variant in GJC2-associated Pelizaeus-Merzbacher-like disease. Mol Genet Metab 2011; 104:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Combes P, Kammoun N, Monnier A, et al. Relevance of GJC2 promoter mutation in Pelizaeus-Merzbacher-like disease. Ann Neurol 2012; 71:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osaka H, Hamanoue H, Yamamoto R, et al. Disrupted SOX10 regulation of GJC2 transcription causes Pelizaeus-Merzbacher-like disease. Ann Neurol 2010; 68:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaurs-Barrière C, Deville M, Sarret C, et al. Pelizaeus-Merzbacher-Like disease presentation of MCT8 mutated male subjects. Ann Neurol 2009; 65:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heuer H, Visser TJ. Minireview: Pathophysiological importance of thyroid hormone transporters. Endocrinology 2009; 150:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf NI, Salomons GS, Rodenburg RJ, et al. Mutations in RARS cause hypomyelination. Ann Neurol 2014; 76:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson MG, Towner JW, Forsman I, Siris E. Syndromes associated with deletion of the long arm of chromosome 18[del(18q)]. Am J Med Genet 1979; 3:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loevner LA, Shapiro RM, Grossman RI, et al. White matter changes associated with deletions of the long arm of chromosome 18 (18q- syndrome): a dysmyelinating disorder? AJNR Am J Neuroradiol 1996; 17:1843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Häusler M, Anhuf D, Schüler H, et al. White-matter disease in 18q deletion (18q-) syndrome: magnetic resonance spectroscopy indicates demyelination or increased myelin turnover rather than dysmyelination. Neuroradiology 2005; 47:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lancaster JL, Cody JD, Andrews T, et al. Myelination in children with partial deletions of chromosome 18q. AJNR Am J Neuroradiol 2005; 26:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Knaap MS, Naidu S, Pouwels PJ, et al. New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum. AJNR Am J Neuroradiol 2002; 23:1466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Knaap MS, Linnankivi T, Paetau A, et al. Hypomyelination with atrophy of the basal ganglia and cerebellum: follow-up and pathology. Neurology 2007; 69:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zara F, Biancheri R, Bruno C, et al. Deficiency of hyccin, a newly identified membrane protein, causes hypomyelination and congenital cataract. Nat Genet 2006; 38:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biancheri R, Zara F, Bruno C, et al. Phenotypic characterization of hypomyelination and congenital cataract. Ann Neurol 2007; 62:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daoud H, Tétreault M, Gibson W, et al. Mutations in POLR3A and POLR3B are a major cause of hypomyelinating leukodystrophies with or without dental abnormalities and/or hypogonadotropic hypogonadism. J Med Genet 2013; 50:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf NI, Harting I, Boltshauser E, et al. Leukoencephalopathy with ataxia, hypodontia, and hypomyelination. Neurology 2005; 64:1461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Timmons M, Tsokos M, Asab MA, et al. Peripheral and central hypomyelination with hypogonadotropic hypogonadism and hypodontia. Neurology 2006; 67:2066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauhari P, Sahu JK, Singhi P, et al. An Indian boy with a novel leukodystrophy: 4H syndrome. J Child Neurol 2014; 29:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orcesi S, Tonduti D, Uggetti C, et al. New case of 4H syndrome and a review of the literature. Pediatr Neurol 2010; 42:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atrouni S, Darazé A, Tamraz J, et al. Leukodystrophy associated with oligodontia in a large inbred family: fortuitous association or new entity? Am J Med Genet A 2003; 118A:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf NI, Harting I, Innes AM, et al. Ataxia, delayed dentition and hypomyelination: a novel leukoencephalopathy. Neuropediatrics 2007; 38:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernard G, Thiffault I, Tetreault M, et al. Tremor-ataxia with central hypomyelination (TACH) leukodystrophy maps to chromosome 10q22.3-10q23.31. Neurogenetics 2010; 11:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sasaki M, Takanashi J, Tada H, et al. Diffuse cerebral hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum. Brain Dev 2009; 31:582.
          </a>
         </li>
         <li class="breakAll">
          Bernard G, Vanderver A. Pol III-related leukodystrophies. GeneReviews 2012. www.ncbi.nlm.nih.gov/books/NBK99167/ (Accessed on January 21, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Piana R, Tonduti D, Gordish Dressman H, et al. Brain magnetic resonance imaging (MRI) pattern recognition in Pol III-related leukodystrophies. J Child Neurol 2014; 29:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aula P, Autio S, Raivio KO, et al. "Salla disease": a new lysosomal storage disorder. Arch Neurol 1979; 36:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haataja L, Parkkola R, Sonninen P, et al. Phenotypic variation and magnetic resonance imaging (MRI) in Salla disease, a free sialic acid storage disorder. Neuropediatrics 1994; 25:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schleutker J, Leppänen P, Månsson JE, et al. Lysosomal free sialic acid storage disorders with different phenotypic presentations--infantile-form sialic acid storage disease and Salla disease--represent allelic disorders on 6q14-15. Am J Hum Genet 1995; 57:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sonninen P, Autti T, Varho T, et al. Brain involvement in Salla disease. AJNR Am J Neuroradiol 1999; 20:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varho TT, Alajoki LE, Posti KM, et al. Phenotypic spectrum of Salla disease, a free sialic acid storage disorder. Pediatr Neurol 2002; 26:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battistella PA, Peserico A. Central nervous system dysmyelination in PIBI(D)S syndrome: a further case. Childs Nerv Syst 1996; 12:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon HK, Sargent MA, Prendiville JS, Poskitt KJ. Cerebellar and cerebral atrophy in trichothiodystrophy. Pediatr Radiol 2005; 35:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Knaap MS, Smit LM, Barth PG, et al. Magnetic resonance imaging in classification of congenital muscular dystrophies with brain abnormalities. Ann Neurol 1997; 42:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Haren K, Bonkowsky JL, Bernard G, et al. Consensus statement on preventive and symptomatic care of leukodystrophy patients. Mol Genet Metab 2015; 114:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wishnew J, Page K, Wood S, et al. Umbilical cord blood transplantation to treat Pelizaeus-Merzbacher Disease in 2 young boys. Pediatrics 2014; 134:e1451.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1693 Version 18.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Uber eine eigenthümliche form spastischer Lähmung mit cerebralerscheinungen auf hereditärer Grundlage (Multiple Sklerose)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9894878" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pelizaeus-Merzbacher disease: three novel mutations and implication for locus heterogeneity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Eine eigenartige familiar-hereditäre Erkrankungsform (Aplasia axialis extra-corticalis congenital)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7530633" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Genetics of Pelizaeus-Merzbacher disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14572140" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pelizaeus-Merzbacher disease and spastic paraplegia type 2: two faces of myelin loss from mutations in the same gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14572140" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pelizaeus-Merzbacher disease and spastic paraplegia type 2: two faces of myelin loss from mutations in the same gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10588103" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : MR-revealed myelination in the cerebral corticospinal tract as a marker for Pelizaeus-Merzbacher's disease with proteolipid protein gene duplication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2773936" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pelizaeus-Merzbacher disease: an X-linked neurologic disorder of myelin metabolism with a novel mutation in the gene encoding proteolipid protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2773936" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pelizaeus-Merzbacher disease: an X-linked neurologic disorder of myelin metabolism with a novel mutation in the gene encoding proteolipid protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35885014" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mutation of Proteolipid Protein 1 Gene: From Severe Hypomyelinating Leukodystrophy to Inherited Spastic Paraplegia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10818135" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The evolution of lipophilin genes from invertebrates to tetrapods: DM-20 cannot replace proteolipid protein in CNS myelin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9367291" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Duplication of proteolipid protein gene: a possible major cause of Pelizaeus-Merzbacher disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9008538" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Mutations in the proteolipid protein gene in Japanese families with Pelizaeus-Merzbacher disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11723390" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : An update on the leukodsytrophies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12196561" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Myelin proteolipid protein forms a complex with integrins and may participate in integrin receptor signaling in oligodendrocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10417279" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Proteolipoprotein gene analysis in 82 patients with sporadic Pelizaeus-Merzbacher Disease: duplications, the major cause of the disease, originate more frequently in male germ cells, but point mutations do not. The Clinical European Network on Brain Dysmyelinating Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17115121" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10319885" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Proteolipid protein gene duplications causing Pelizaeus-Merzbacher disease: molecular mechanism and phenotypic manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17938374" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Lipid rafts, protein scaffolds, and neurologic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11276122" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Molecular pathways of oligodendrocyte apoptosis revealed by mutations in the proteolipid protein gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8696336" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A cellular mechanism governing the severity of Pelizaeus-Merzbacher disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9472043" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660364" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The burden of inherited leukodystrophies in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32573057" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Estimating the relative frequency of leukodystrophies and recommendations for carrier screening in the era of next-generation sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24532200" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Epidemiological, clinical, and genetic landscapes of hypomyelinating leukodystrophies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3598129" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pelizaeus-Merzbacher disease: clinical and nosological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11093273" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Genotype-phenotype correlation in inherited brain myelination defects due to proteolipid protein gene mutations. Clinical European Network on Brain Dysmyelinating Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11872612" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16778599" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Quantifying the carrier female phenotype in Pelizaeus-Merzbacher disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10319897" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Novel exon 3B proteolipid protein gene mutation causing late-onset spastic paraplegia type 2 with variable penetrance in female family members.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25789183" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Unusual presentation of pelizaeus-merzbacher disease: female patient with deletion of the proteolipid protein 1 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15868466" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Magnetic resonance techniques in the assessment of myelin and myelination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15868466" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Magnetic resonance techniques in the assessment of myelin and myelination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19237705" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Invited article: an MRI-based approach to the diagnosis of white matter disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27179222" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pelizaeus-Merzbacher disease in patients with molecularly confirmed diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26774704" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The magnetic resonance imaging spectrum of Pelizaeus-Merzbacher disease: A multicenter study of 19 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9588530" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : An MRI and MRS study of Pelizaeus-Merzbacher disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7619021" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : X-linked pure familial spastic paraparesis. Characterization of a large kindred with magnetic resonance imaging studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9934976" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Different mutations in the same codon of the proteolipid protein gene, PLP, may help in correlating genotype with phenotype in Pelizaeus-Merzbacher disease/X-linked spastic paraplegia (PMD/SPG2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11274318" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Evidence for neuroaxonal injury in patients with proteolipid protein gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12910435" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Degree of hypomyelination and magnetic resonance spectroscopy findings in patients with Pelizaeus Merzbacher phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11805250" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Brain N-acetylaspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10520936" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The molecular pathogenesis of Pelizaeus-Merzbacher disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25749076" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Complex genomic rearrangements at the PLP1 locus include triplication and quadruplication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22490426" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pelizaeus-Merzbacher disease caused by a duplication-inverted triplication-duplication in chromosomal segments including the PLP1 region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25655951" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11787038" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Prenatal interphase FISH diagnosis of PLP1 duplication associated with Pelizaeus-Merzbacher disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11536268" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Prenatal diagnosis of Pelizaeus-Merzbacher disease: detection of proteolipid protein gene duplication by quantitative fluorescent multiplex PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12424770" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prenatal diagnosis of Pelizaeus-Merzbacher disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15192806" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16969684" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Frameshift mutation in GJA12 leading to nystagmus, spastic ataxia and CNS dys-/demyelination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17344063" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Loss-of-function GJA12/Connexin47 mutations cause Pelizaeus-Merzbacher-like disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18094336" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : GJA12 mutations are a rare cause of Pelizaeus-Merzbacher-like disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21959080" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Promoter mutation is a common variant in GJC2-associated Pelizaeus-Merzbacher-like disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21246605" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Relevance of GJC2 promoter mutation in Pelizaeus-Merzbacher-like disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20695017" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Disrupted SOX10 regulation of GJC2 transcription causes Pelizaeus-Merzbacher-like disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19194886" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pelizaeus-Merzbacher-Like disease presentation of MCT8 mutated male subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19179441" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Minireview: Pathophysiological importance of thyroid hormone transporters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24777941" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Mutations in RARS cause hypomyelination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/474629" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Syndromes associated with deletion of the long arm of chromosome 18[del(18q)].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8933867" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : White matter changes associated with deletions of the long arm of chromosome 18 (18q- syndrome): a dysmyelinating disorder?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15645149" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : White-matter disease in 18q deletion (18q-) syndrome: magnetic resonance spectroscopy indicates demyelination or increased myelin turnover rather than dysmyelination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15760848" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Myelination in children with partial deletions of chromosome 18q.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12372733" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17620549" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Hypomyelination with atrophy of the basal ganglia and cerebellum: follow-up and pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16951682" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Deficiency of hyccin, a newly identified membrane protein, causes hypomyelination and congenital cataract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17683097" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Phenotypic characterization of hypomyelination and congenital cataract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23355746" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Mutations in POLR3A and POLR3B are a major cause of hypomyelinating leukodystrophies with or without dental abnormalities and/or hypogonadotropic hypogonadism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15851747" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Leukoencephalopathy with ataxia, hypodontia, and hypomyelination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17159124" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Peripheral and central hypomyelination with hypogonadotropic hypogonadism and hypodontia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23307887" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : An Indian boy with a novel leukodystrophy: 4H syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20399393" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : New case of 4H syndrome and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12605447" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Leukodystrophy associated with oligodontia in a large inbred family: fortuitous association or new entity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17712733" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Ataxia, delayed dentition and hypomyelination: a novel leukoencephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20640464" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Tremor-ataxia with central hypomyelination (TACH) leukodystrophy maps to chromosome 10q22.3-10q23.31.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18851904" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Diffuse cerebral hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18851904" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Diffuse cerebral hypomyelination with cerebellar atrophy and hypoplasia of the corpus callosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24105487" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Brain magnetic resonance imaging (MRI) pattern recognition in Pol III-related leukodystrophies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/420628" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : "Salla disease": a new lysosomal storage disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7885532" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Phenotypic variation and magnetic resonance imaging (MRI) in Salla disease, a free sialic acid storage disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7573051" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Lysosomal free sialic acid storage disorders with different phenotypic presentations--infantile-form sialic acid storage disease and Salla disease--represent allelic disorders on 6q14-15.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10219409" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Brain involvement in Salla disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11992753" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Phenotypic spectrum of Salla disease, a free sialic acid storage disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8674078" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Central nervous system dysmyelination in PIBI(D)S syndrome: a further case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15912410" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Cerebellar and cerebral atrophy in trichothiodystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9225685" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Magnetic resonance imaging in classification of congenital muscular dystrophies with brain abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25577286" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Consensus statement on preventive and symptomatic care of leukodystrophy patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25287453" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Umbilical cord blood transplantation to treat Pelizaeus-Merzbacher Disease in 2 young boys.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
